Structures by: Velaga S. P.
Total: 20
Acesulfame Form I
C4H5NO4S
Chemical Communications (2010) 46, 20 3562-3564
a=7.4940(15)Å b=11.784(2)Å c=15.238(3)Å
α=90.00° β=101.36(3)° γ=90.00°
Acesulfame Form II
C4H5NO4S
Chemical Communications (2010) 46, 20 3562-3564
a=6.3310(2)Å b=7.4720(3)Å c=7.7150(3)Å
α=62.5460(15)° β=73.1710(18)° γ=77.874(2)°
C24H22N4O11
C24H22N4O11
CrystEngComm (2012) 14, 15 5078
a=7.2120(6)Å b=27.7094(17)Å c=12.0909(9)Å
α=90.00° β=91.789(8)° γ=90.00°
Nitrofurantoin:citric acid cocrystal
C8H6N4O5,C6H8O7
CrystEngComm (2012) 14, 15 5078
a=13.444(1)Å b=11.480(1)Å c=12.434(1)Å
α=90.000° β=113.736(1)° γ=90.000°
Ezetimibe
C24H21F2NO3
CrystEngComm (2014) 16, 38 8984
a=5.9510(19)Å b=15.899(5)Å c=21.400(16)Å
α=90° β=90° γ=90°
Ezetimibe-Imidazole
C24H21F2NO3,C3H4N2
CrystEngComm (2014) 16, 38 8984
a=5.8320(2)Å b=15.7520(5)Å c=25.6730(13)Å
α=90° β=90° γ=90°
Ezetimibe-Formamide
C24H21F2N1O3,C1H3N1O1
CrystEngComm (2014) 16, 38 8984
a=6.1400(2)Å b=17.0770(7)Å c=21.3500(12)Å
α=90° β=90° γ=90°
1-Ethyl-6-fluoro-7-(4-formylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline- 3-carboxylic acid
C17H18FN3O4
Acta Crystallographica Section E (2007) 63, 11 o4281-o4281
a=8.6689(17)Å b=9.6727(19)Å c=10.142(2)Å
α=73.41(3)° β=81.41(3)° γ=86.48(3)°
4-(3-carboxy-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-quinolyl)piperazinium dihydrogen phosphate monohydrate
C16H19FN3O3,H2O4P,H2O
Acta Crystallographica Section C (2007) 63, 12 o731-o733
a=7.1918(14)Å b=8.9400(18)Å c=15.792(3)Å
α=103.81(3)° β=94.01(3)° γ=106.51(3)°
4-(3-carboxy-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-quinolyl)piperazinium dihydrogen phosphate monohydrate
C17H19FN3O3,H2O4P,H2O
Acta Crystallographica Section C (2007) 63, 12 o731-o733
a=7.2582(15)Å b=8.9979(18)Å c=15.712(3)Å
α=100.93(3)° β=96.00(3)° γ=105.74(3)°
{3-[4-(aminocarbonylmethyl)phenoxy]-2-hydroxypropyl)isopropylammonium 4-aminobenzoate monohydrate
C14H23N2O3,C7H6NO2,H2O
Acta Crystallographica Section C (2007) 63, 12 o714-o716
a=28.547(6)Å b=7.4223(15)Å c=23.822(5)Å
α=90.00° β=122.34(3)° γ=90.00°
C25H22ClN3O5
C25H22ClN3O5
The Journal of Physical Chemistry. C, Nanomaterials and Interfaces (2013) 13, 12258-12265
a=27.3847(10)Å b=5.01906(16)Å c=17.1935(6)Å
α=90.0° β=97.3103(20)° γ=90.0°
Urea:succinic acid cocrystal
C4H6O4,CH4N2O
Crystal Growth & Design (2010) 10, 11 4847
a=18.7250(11)Å b=6.5120(7)Å c=6.4210(5)Å
α=90.00° β=90.834(6)° γ=90.00°
Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro -2,6-dimethyl-3,5-pyridinedicarboxylate formamide
C18H19Cl2NO4,CH3ON
Crystal Growth & Design (2009) 9, 3 1254
a=9.6360(19)Å b=11.335(2)Å c=11.685(2)Å
α=100.99(3)° β=112.09(3)° γ=107.52(3)°
Felodipine
C72H76Cl8N4O16
Crystal Growth & Design (2009) 9, 3 1254
a=32.392(7)Å b=18.717(4)Å c=23.711(5)Å
α=90.00° β=91.00(3)° γ=90.00°
Norfloxacin
C16H18FN3O3
Crystal Growth & Design (2006) 6, 12 2699
a=4.3240(10)Å b=9.6350(10)Å c=18.0890(10)Å
α=78.514(10)° β=87.121(10)° γ=80.574(10)°
Norfloxacin.isonicotinamide.CHCL3
C16H18FN3O3,C6H6N2O,CHCl3
Crystal Growth & Design (2006) 6, 12 2699
a=18.8749(7)Å b=14.6353(6)Å c=18.4094(4)Å
α=90.00° β=98.432(2)° γ=90.00°
Norfloxacinmalonate dihydrate
C16H19FN3O3,C3H3O4,2(H2O)
Crystal Growth & Design (2006) 6, 12 2699
a=8.2170(1)Å b=9.1380(2)Å c=13.8830(2)Å
α=90.3920(10)° β=91.0800(10)° γ=96.7710(10)°
Norfloxacinmaleate hydrate
C16H19FN3O3,C4H3O4,H2O
Crystal Growth & Design (2006) 6, 12 2699
a=7.0890(2)Å b=9.8742(3)Å c=14.5854(3)Å
α=96.457(2)° β=92.300(2)° γ=102.937(2)°
Norfloxacin (succinate)0.5 hydrate
C16H19FN3O3,0.5(C4H4O4),H2O
Crystal Growth & Design (2006) 6, 12 2699
a=6.8086(2)Å b=9.3743(3)Å c=15.5127(4)Å
α=93.690(2)° β=93.262(2)° γ=110.885(2)°